Balance between somatostatin and D2 receptor expression drives TSH‐secreting adenoma response to somatostatin analogues and dopastatins

F Gatto, F Barbieri, M Gatti, R Wurth… - Clinical …, 2012 - Wiley Online Library
Context First‐line therapy for thyrotropin‐secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …
被引用次数：63 相关文章

Balance between somatostatin and D2 receptor expression drives TSH‐secreting adenoma response to somatostatin analogues and dopastatins

F Gatto, F Barbieri, M Gatti, R Wurth, S Schulz… - Clinical …, 2012 - infona.pl
Context First‐line therapy for thyrotropin‐secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins

F Gatto, F Barbieri, A Gatti, R Wurth, S Schulz… - Clinical …, 2012 - repub.eur.nl
Context First-line therapy for thyrotropin-secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins

F Gatto, F Barbieri, M Gatti, R Wurth… - Clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
Context First-line therapy for thyrotropin-secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …
[PDF] academia.edu

[PDF][PDF] Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins

F Gatto, F Barbieri, M Gatti, R Wurth, S Schulz… - Clinical …, 2011 - academia.edu
Context First-line therapy for thyrotropin-secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins

F Gatto, F Barbieri, M Gatti, R Wurth, S Schulz… - Clinical …, 2012 - hero.epa.gov
CONTEXT: First-line therapy for thyrotropin-secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …

Balance between somatostatin and D2 receptor expression drives TSH‐secreting adenoma response to somatostatin analogues and dopastatins

F Gatto, F Barbieri, M Gatti, R Wurth, S Schulz… - Clinical …, 2012 - cir.nii.ac.jp
抄録< jats: title> Summary</jats: title>< jats: p>< jats: bold> Context</jats: bold> First‐line
therapy for thyrotropin‐secreting pituitary adenomas (TSHomas) is neurosurgery, while …

[引用][C] Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins

F GATTO, F BARBIERI, F MINUTO… - Clinical …, 2012 - pascal-francis.inist.fr
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma
response to somatostatin analogues and dopastatins CNRS Inist Pascal-Francis CNRS …

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

F Gatto, F Barbieri, M Gatti, R Wurth, S Schulz… - Clinical …, 2012 - europepmc.org
Objective We evaluated somatostatin 1, 2, 3 and 5 and dopamine D2 receptor expression in
tumour samples from three TSHomas, and the relationships between receptor expression, in …

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

F Gatto, F Barbieri, M Gatti, R Wurth… - Clinical …, 2012 - search.ebscohost.com
Context First-line therapy for thyrotropin-secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …